Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Salem-Spencer, Susan
S-CitAD, NCT03108846: Escitalopram for Agitation in Alzheimer's Disease	Active, not recruiting	3	187	Canada, US	Escitalopram, Lexapro, Placebo, non-applicable	JHSPH Center for Clinical Trials, National Institute on Aging (NIA)	Dementia	04/24	05/25
RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease	Completed	3	804	Canada, US, RoW	Simufilam, PTI-125, Placebo	Cassava Sciences, Inc., Premier Research Group plc	Alzheimer Disease	10/24	10/24
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease	Completed	2/3	554	US	ATH-1017, Placebo	Athira Pharma	Alzheimer Disease, Dementia of Alzheimer Type	07/24	07/24
SIGNAL-AD, NCT04381468: SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)	Completed	1/2	50	US	Pepinemab, Placebo	Vaccinex Inc., Alzheimer's Drug Discovery Foundation, Alzheimer's Association	Alzheimer Disease	06/24	06/24